Results 171 to 180 of about 7,735 (207)

Designing immunoconjugates for cancer therapy

Expert Opinion on Biological Therapy, 2012
Antibody-drug conjugates (ADCs), as well as antibody conjugates of protein toxins (immunotoxins) and cytokines (immunocytokines), are showing clinical efficacy, with manageable toxicities, in cancer treatment.The utility of an ADC is governed by the antibody and the target, as well as by the drug-linker component of the conjugate. The conjugation site,
Serengulam V, Govindan, David M, Goldenberg   +1 more
openaire   +2 more sources

Naptumomab estafenatox: a new immunoconjugate

Expert Opinion on Biological Therapy, 2010
New agents that specifically engage the immune system are being tested in a variety of malignancies. This review provides an overview of naptumomab, an immunotoxin, with encouraging clinical activity in Phase I trials.This review examines the preclinical and the published clinical data with regards to naptumomab.This review provides the reader with an ...
Matthew K, Robinson, R Katherine, Alpaugh, Hossein, Borghaei   +2 more
openaire   +2 more sources

Internalization of an intact doxorubicin immunoconjugate

Cancer Immunology, Immunotherapy, 1994
An immunoconjugate between doxorubicin and anti-(carcinoembryonic antigen) (CEA) was prepared by using aminodextran (M(r) = 40,000) as the intermediate carrier, and the carbohydrate moiety of the antibody as the linking site. The resulting immunoconjugate was subjected to an in vitro evaluation for the internalization on the target cells (Lo Vo), and ...
L B, Shih, D M, Goldenberg, H, Xuan, H W, Lu, M J, Mattes, T C, Hall   +5 more
openaire   +2 more sources

Synthesis of an immunoconjugate of camptothecin

Bioorganic & Medicinal Chemistry Letters, 2002
The first immunoconjugate of camptothecin has been synthesized wherein the drug is attached to the tumor-recognizing antibody BR96 via a Cathepsin B cleavable linker. Endocytosis of the immunoconjugate upon binding to the tumor cell followed by enzymatic cleavage of the linker inside the endosome ensures tumor-specific release of the drug. In this way,
Michael A, Walker, Gene M, Dubowchik, Sandra J, Hofstead, Pamela A, Trail, Raymond A, Firestone   +4 more
openaire   +2 more sources

Anti-Human Immunodeficiency Virus Immunoconjugates

1995
Publisher Summary A number of approaches have been developed to use immunological targeting to deliver anti-HIV agents to HIV-infected cells. The efficacy of these approaches has been convincingly demonstrated in vitro. Methods have been developed that allow for a significant enhancement of the in vitro efficacy of these immunoconjugates by using ...
S H, Pincus, V V, Tolstikov
openaire   +2 more sources

Cytotoxicity of 213Bi- and 225Ac-immunoconjugates

Nuclear Medicine Communications, 1995
This paper describes in vitro cytotoxicity experiments with 213Bi- and 225Ac-immunoconjugates on the human epidermoid tumour cell line A431 using a blood group A-reactive murine IgG (2D11) as the specific antibody and MOPC 21 as the control antibody. With both radionuclides, specific cell-killing was achieved. The observed cytotoxicity of 213Bi (T1/2 -
F M, Kaspersen, E, Bos, A V, Doornmalen, M W, Geerlings, C, Apostolidis, R, Molinet   +5 more
openaire   +2 more sources

Stabilization of Chimeric BR96-Doxorubicin Immunoconjugate

Pharmaceutical Research, 1995
Chimeric BR96-doxorubicin conjugate (BR96-DOX) is an immunoconjugate designed to specifically target and kill certain tumor cells. The linker between the chimeric BR96 antibody and DOX is an acid-labile hydrazone group which was designed to undergo lysosomal hydrolysis to release DOX in vivo.
N P, Barbour, M, Paborji, T C, Alexander, W P, Coppola, J B, Bogardus   +4 more
openaire   +2 more sources

Radioimmunotherapy with Alpha-Particle-Emitting Immunoconjugates

Science, 1988
Alpha particles are energetic short-range ions whose higher linear energy transfer produces extreme cytotoxicity. An α-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared.
R M, Macklis, B M, Kinsey, A I, Kassis, J L, Ferrara, R W, Atcher, J J, Hines, C N, Coleman, S J, Adelstein, S J, Burakoff   +8 more
openaire   +2 more sources

Intraperitoneal immunoconjugates.

Cancer research, 1990
Intracavitary instillation of radioantibodies has been proposed as therapy for anatomically confined malignant disease. To evaluate this therapeutic strategy, a monoclonal antibody reactive with human transferrin receptor (7D3) was evaluated for localization in a human malignant mesothelioma transplanted i.p. in athymic nude mice.
T W, Griffin, J, Collins, F, Bokhari, M, Stochl, A B, Brill, T, Ito, G, Emond, H, Sands   +7 more
openaire   +1 more source